KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Accumulated Expenses: 2010-2025

Historic Other Accumulated Expenses for Emergent BioSolutions (EBS) over the last 7 years, with Sep 2025 value amounting to $24.1 million.

  • Emergent BioSolutions' Other Accumulated Expenses fell 64.35% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year decrease of 64.35%. This contributed to the annual value of $27.7 million for FY2024, which is 15.29% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Other Accumulated Expenses stood at $24.1 million, which was up 77.21% from $13.6 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Other Accumulated Expenses peaked at $122.0 million during Q1 2021, and registered a low of $11.1 million during Q1 2025.
  • For the 3-year period, Emergent BioSolutions' Other Accumulated Expenses averaged around $27.1 million, with its median value being $25.2 million (2023).
  • In the last 5 years, Emergent BioSolutions' Other Accumulated Expenses skyrocketed by 1,505.26% in 2021 and then slumped by 79.84% in 2022.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Other Accumulated Expenses stood at $73.1 million in 2021, then crashed by 37.21% to $45.9 million in 2022, then fell by 28.76% to $32.7 million in 2023, then dropped by 15.29% to $27.7 million in 2024, then slumped by 64.35% to $24.1 million in 2025.
  • Its Other Accumulated Expenses was $24.1 million in Q3 2025, compared to $13.6 million in Q2 2025 and $11.1 million in Q1 2025.